论文部分内容阅读
多拉韦林(doravirine MK-1439)是默克公司开发的实验性新一代非核苷类逆转录酶抑制剂,用于治疗艾滋病感染,临床前研究表现出强抗艾滋病病毒活性。药代动力学参数支持1次/d用药,无食物效应。48周Ⅱb期临床试验为随机、双盲和剂量范围研究,包括2个部分。第1部分为剂量范围研究:此药(n=166)的4个剂量组(25、50、100和200 mg)或依法韦仑(efavirenz)(n=42),均伍用泰诺福韦/恩曲他滨。第2部分为扩展期研究(n=132):多拉韦林(n=66)100 mg组或依法韦仑组(n=66),这些也均伍用泰诺福韦/恩
Doravirine MK-1439 is an experimental new generation of non-nucleoside reverse transcriptase inhibitor developed by Merck for the treatment of AIDS infection. Preclinical studies have shown strong anti-HIV activity. Pharmacokinetic parameters support 1 / d medication, no food effect. The 48-week phase IIb clinical trial was a randomized, double-blind, and dose-range study consisting of 2 parts. The first part is a dose range study: Four doses (25, 50, 100 and 200 mg) of this drug (n = 166) or efavirenz (n = 42) Emtricitabine. The second part was extended-phase study (n = 132): dolavavir (n = 66) 100 mg or efavirenz (n = 66)